-
1
Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine
Published 2023-04-01Subjects: “…hr+/her2− breast cancer…”
Get full text
Article -
2
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Published 2024-01-01Subjects: “…HR + /HER2- breast cancer…”
Get full text
Article -
3
Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer
Published 2024-12-01Subjects: Get full text
Article -
4
-
5
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
Published 2024-05-01Subjects: “…hr+/her2− breast cancer…”
Get full text
Article -
6
Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis
Published 2024-02-01Subjects: Get full text
Article -
7
Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer
Published 2024-11-01Subjects: Get full text
Article -
8
Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
Published 2023-05-01Subjects: “…HR+/HER2- breast cancer…”
Get full text
Article -
9
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
Published 2022-09-01Subjects: “…metastatic HR+/HER2-breast cancer…”
Get full text
Article -
10
-
11
METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer
Published 2023-02-01Subjects: “…HR+HER2− breast cancer…”
Get full text
Article -
12
-
13
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
Published 2024-01-01Subjects: “…HR+/HER2-breast cancer…”
Get full text
Article -
14
The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
Published 2024-01-01Subjects: Get full text
Article